drugset / Trial / NCT04152148
A Phase I Clinical Trial of BAT4306F on Safety, Tolerability and Pharmacokinetics for Patients
Non-randomizedSequentialOpen-labelTreatment
Summary
The primary objective of the study is to evaluate the safety and tolerability of BAT4306F in patients with CD20-positive B-cell lymphoma
Timeline
- Start
- 2018-09-04
- Primary completion
- 2021-01-13
- Completion
- 2021-01-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BAT4306F | Unknown | 500 mg | — |
| Subject | BAT4306F | Unknown | 750 mg | — |
| Subject | BAT4306F | Unknown | 900 mg | — |
| Subject | BAT4306F | Unknown | 1000 mg | — |